Japanese nationwide questionnaire survey on delayed cerebral infarction due to vasospasm after subarachnoid hemorrhage.
aneurysmal
cerebral vasospasm
cilostazol
coil embolization
delayed cerebral infarction
subarachnoid hemorrhage
survey
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
09
2023
accepted:
09
10
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Various prophylactic drugs for cerebral vasospasm and delayed cerebral infarction (DCI) after subarachnoid hemorrhage (SAH) have been used in Japan. To investigate the treatment trends for cerebral vasospasm and frequency of DCI after SAH throughout Japan in 2021. In 2021 we conducted an anonymous questionnaire survey on management for preventing cerebral vasospasm after aneurysmal SAH, and the frequency of DCI. The questionnaire was emailed to 955 certified neurosurgeons at 553 hospitals in Japan. Of them, 162 hospitals (29% response rate) responded to the questionnaire. Of these, 158 were included in this study, while four hospitals that responded insufficiently were excluded. The efficacy of treatments for reducing DCI were examined through a logistic regression analysis. Among 3,093 patients treated with aneurysmal SAH, 281 patients (9.1%) were diagnosed with DCI related to cerebral vasospasm. Coil embolization had significantly lower DCI frequency (6.9%), compared to microsurgical clipping (11.8%, odds ratio, 0.90; 95% confidential intervals, 0.84-0.96; This study elucidated the trends in prophylactic drugs to prevent cerebral vasospasm and frequency of DCI after aneurysmal SAH in Japan. Coil embolization and cilostazol administration showed effectiveness in reducing DCI related to cerebral vasospasm in 2021.
Sections du résumé
Background and purpose
UNASSIGNED
Various prophylactic drugs for cerebral vasospasm and delayed cerebral infarction (DCI) after subarachnoid hemorrhage (SAH) have been used in Japan. To investigate the treatment trends for cerebral vasospasm and frequency of DCI after SAH throughout Japan in 2021.
Methods
UNASSIGNED
In 2021 we conducted an anonymous questionnaire survey on management for preventing cerebral vasospasm after aneurysmal SAH, and the frequency of DCI. The questionnaire was emailed to 955 certified neurosurgeons at 553 hospitals in Japan. Of them, 162 hospitals (29% response rate) responded to the questionnaire. Of these, 158 were included in this study, while four hospitals that responded insufficiently were excluded. The efficacy of treatments for reducing DCI were examined through a logistic regression analysis.
Results
UNASSIGNED
Among 3,093 patients treated with aneurysmal SAH, 281 patients (9.1%) were diagnosed with DCI related to cerebral vasospasm. Coil embolization had significantly lower DCI frequency (6.9%), compared to microsurgical clipping (11.8%, odds ratio, 0.90; 95% confidential intervals, 0.84-0.96;
Conclusions
UNASSIGNED
This study elucidated the trends in prophylactic drugs to prevent cerebral vasospasm and frequency of DCI after aneurysmal SAH in Japan. Coil embolization and cilostazol administration showed effectiveness in reducing DCI related to cerebral vasospasm in 2021.
Identifiants
pubmed: 38020653
doi: 10.3389/fneur.2023.1296995
pmc: PMC10654625
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1296995Informations de copyright
Copyright © 2023 Nishikawa, Yamada, Uchida, Yamanaka, Hayashi, Katano, Tanikawa, Iwama, Iihara, Morioka and Mase.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neurosurg Rev. 2022 Apr;45(2):1291-1302
pubmed: 34870768
Cerebrovasc Dis. 2022;51(2):138-148
pubmed: 35288494
Neurol Med Chir (Tokyo). 2022 May 15;62(5):223-230
pubmed: 35418528
Cerebrovasc Dis. 2004;17(1):53-60
pubmed: 14530638
World Neurosurg. 2021 Jun;150:161-170
pubmed: 33631387
J Clin Neurosci. 2022 May;99:190-203
pubmed: 35286971
Neurosurgery. 2007 Apr;60(4):658-67; discussion 667
pubmed: 17415202
Stroke. 2023 Jul;54(7):e314-e370
pubmed: 37212182
Cerebrovasc Dis. 2016;42(1-2):97-105
pubmed: 27070952
J Stroke Cerebrovasc Dis. 2018 Nov;27(11):2979-2985
pubmed: 30093204
J Cereb Blood Flow Metab. 2011 Jul;31(7):1545-53
pubmed: 21505477
J Neurosurg. 2013 Jan;118(1):121-30
pubmed: 23039152
Neurol Med Chir (Tokyo). 2019 Dec 15;59(12):449-491
pubmed: 31801934
J Neurosurg. 2022 Apr 01;137(6):1707-1717
pubmed: 35364589
Neurosurgery. 2020 Feb 1;86(2):E175-E183
pubmed: 31501886
Cerebrovasc Dis. 2011;32(1):89-93
pubmed: 21677432
World Neurosurg. 2017 Nov;107:630-640
pubmed: 28843762
Stroke. 2013 Jan;44(1):29-37
pubmed: 23238862
J Neurol Sci. 2014 Jan 15;336(1-2):146-51
pubmed: 24211059
Stroke. 2010 Nov;41(11):2519-24
pubmed: 20813994
World Neurosurg. 2015 Dec;84(6):1798-803
pubmed: 26278868
J Vasc Interv Neurol. 2018 Nov;10(2):33-40
pubmed: 30746008
Lancet Neurol. 2011 Jul;10(7):618-25
pubmed: 21640651
Cerebrovasc Dis. 2017;44(1-2):59-67
pubmed: 28463833
BMC Neurol. 2022 Dec 20;22(1):492
pubmed: 36539711
Int J Stroke. 2022 Oct;17(9):1039-1049
pubmed: 35443847